iXCells Biotechnologies has appointed Steve Smith as Chief Executive Officer, elevating him from his previous role as Chief Commercial Officer (CCO) as the San Diego-based company expands its induced pluripotent stem cell (iPSC) preclinical services portfolio.

leon-nanodrugs GmbH has announced a series of significant developments, closing an oversubscribed financing round whilst appointing two senior scientific leaders, as the Munich-based company accelerates its transition into full commercial deployment of its GMP-compatible nanoparticle manufacturing platform.

Nuclera, the Cambridge-based biotechnology company, and leadXpro, a specialist in structure-based drug discovery head­quartered in Villigen, Switzerland, have announced a scientific partnership aimed at improving access to high-quality membrane protein constructs for drug discovery programmes.

London-based Synthace, a software and services company specialising in assay development, has announced a collaboration with Charles River Laboratories International, Inc., a global provider of drug discovery, development, testing and manufacturing solutions. The partnership will give Charles River’s clients access to Synthace’s approach to developing, automating and transferring assays with greater robustness and efficiency.